A good analysis would be to determine what portion of the drug market would fall in this category. I imagine the amount of drug R&D done with some amount of federal dollars is pretty high.

If this policy has enough teeth to scare pharma corps, then it will probably change their behaviors. They could decide that they need to use minimal federal funding which could slow drug development. I wonder if this policy (or others) is meant to address this potential.